Clinical Trial Update: Open-Label Study of Setmelanotide in Hypothalamic Obesity [Phase 2]

View source ↗

Summary

Rhythm Pharmaceuticals completed an open-label Phase 2 study of setmelanotide in hypothalamic obesity and posted the results in 2023. The update summarizes the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypothalamic Obesity

Drugs mentioned

• IMCIVREE (setmelanotide)

Snippet

Sponsor: Rhythm Pharmaceuticals, Inc. | Conditions: Hypothalamic Obesity | Phase 2 | Status: COMPLETED | Results posted: 2023-09-21